Cerimon receives positive Phase II data on diclofenac patch
This article was originally published in Scrip
Executive Summary
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.